
Standard BioTools Holders Approve Reverse Split Range of 1-for-20 to 1-for-40
The charter amendment sets a ratio range, with the final ratio still to be agreed with Treeline Biosciences.
Standard Biotools Inc. · Nasdaq · Pharmaceutical Preparations

The charter amendment sets a ratio range, with the final ratio still to be agreed with Treeline Biosciences.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 5, 2026 | Thomas D. Carey director | Bought | 75,000 | $0.63 | $46,898 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedStandard BioTools stockholders approve Treeline merger share issuance, 1-for-20 to 1-for-40 reverse split and Mass Cytometry sale
Other events
AI summary, unreviewedStandard BioTools 8-K supplements Treeline merger proxy after 15 demand letters and two New York complaints; Centerview values company at $1.14 per share vs. $0.62 pre-filing market cap